Dengue Vaccine TAK-003 Cleared by DCGI
Recently, Takeda’s dengue vaccine TAK-003 (Qdenga) received clearance from the Subject Expert Committee under the Drugs Controller General of India (DCGI) for use in individuals aged 4-60 years.
- This marks a major milestone in India’s fight against dengue, which causes millions of infections and thousands of hospitalisations annually.
- It has been tested on over 28,000 participants and approved in 40+ countries.
- The vaccine provides strong protection against severe dengue and hospitalisation.
- It does not require pre-vaccination screening, making it easier to deploy in public health programmes.
- However, its effectiveness varies across serotypes, with relatively lower protection against DENV-3 and DENV-4.
- The vaccine ....
Do You Want to Read More?
Subscribe Now
To get access to detailed content
Already a Member? Login here
Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material since 2018 of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Science & Technology
- 1 India Advances Defence Capabilities with Key Procurement Agreements
- 2 Indian Navy Commissions INS Taragiri Stealth Frigate
- 3 Digital Humans
- 4 India Lays Foundation for First Advanced 3D Chip Packaging Unit in Odisha
- 5 IVRI Produces Indigenous Sahiwal Calves Using IVF Technology
- 6 India Demonstrates 1,000-km Quantum Communication Network
- 7 India’s Prototype Fast Breeder Reactor (PFBR) Achieves Criticality
- 8 Indian Navy Inducts ‘Dunagiri’ Stealth Frigate
- 9 Indian Navy Inducts ‘Sanshodhak’
- 10 ‘Malwan’ Anti-Submarine Warfare Shallow Water Craft
